BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Update

BioStem Technologies, Inc. (OTCMKTS:BSEM) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 117,700 shares, a drop of 21.2% from the November 15th total of 149,400 shares. Based on an average trading volume of 197,300 shares, the days-to-cover ratio is presently 0.6 days.

BioStem Technologies Price Performance

OTCMKTS:BSEM traded up 0.97 during mid-day trading on Friday, hitting 17.21. 60,600 shares of the company’s stock were exchanged, compared to its average volume of 38,093. The company has a market cap of $286.05 million, a PE ratio of 25.31 and a beta of -0.62. BioStem Technologies has a one year low of 4.28 and a one year high of 28.26. The business has a fifty day moving average price of 15.25 and a 200 day moving average price of 11.54.

BioStem Technologies (OTCMKTS:BSEM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported 0.32 EPS for the quarter, topping analysts’ consensus estimates of 0.31 by 0.01. The company had revenue of 82.56 million during the quarter, compared to the consensus estimate of 78.22 million. On average, equities analysts forecast that BioStem Technologies will post 1.41 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.